

December 08, 2020

Specialty Ingredients for Nutraceutical & Allied Industry

То	То
The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001	The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051
Code: 540222	Code: LAURUSLABS

Dear Sir/Madam,

Sub: Intimation of Schedule of Analyst/ Institutional Investor Meetings

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Regulations"), the details of Analyst/Institutional Investor meeting to be conducted on December 09, 2020 are as follows:

Date	Analyst / Investors	Type of Interaction
December 09, 2020	J.P. Morgan - India Emerging Opportunities Forum 2020	Group Meetings – Virtual NDR

Note:

1. Date of the aforesaid meetings are subject to change due to exigencies on the part of Investors / Company.

2. No Unpublished Price Sensitive Information will be shared during the meetings.

We request you to please take the same on record.

Thanking You, Yours sincerely, For Laurus Labs Limited

P.

V.V. Ravi Kumar Executive Director & Chief Financial Officer

Active Pharmaceutical Ingredients & Intermediates



Finished Dosage Forms

Registered Office : Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518 T +91 891 660 1222, 306 1222, F +91 891 660 1270, 306 1270, E info@lauruslabs.com W lauruslabs.com

AURUS Generics LAURUS Generics LAURUS Synthesis LAURUS Ingredients

Contract Development & Manufacturing Services